Staphylococcus aureus capsular polysaccharides.
Serotype 5 and 8 capsular polysaccharides predominate among clinical isolates of Staphylococcus aureus. The results of experiments in animal models of infection have revealed that staphylococcal capsules are important in the pathogenesis of S. aureus infections. The capsule enhances staphylococcal virulence by impeding phagocytosis, resulting in bacterial persistence in the bloodstream of infected hosts. S. aureus capsules also promote abscess formation in rats. Although the capsule has been shown to modulate S. aureus adherence to endothelial surfaces in vitro, animal studies suggest that it also promotes bacterial colonization and persistence on mucosal surfaces. S. aureus capsular antigens are surface associated, limited in antigenic specificity, and highly conserved among clinical isolates. With the emergence of vancomycin-resistant S. aureus in the United States in 2002, new strategies are needed to combat staphylococcal infections. Purified serotype 5 and 8 capsular polysaccharides offer promise as target antigens for a vaccine to prevent staphylococcal infections, although the inclusion of other antigens is likely to be essential in the development of an effective S. aureus vaccine. The genetics and mechanisms of capsule biosynthesis are complex, and much work remains to enhance our understanding of capsule biosynthesis and its regulation.
O'Riordan
Katherine
K
Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
Lee
Jean C
JC
D000818:Animals; D016667:Bacterial Capsules / Q000235:genetics / Q000276:immunology / Q000502:physiology*; D001428:Bacterial Vaccines / Q000276:immunology; D006801:Humans; D011135:Polysaccharides, Bacterial / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D013203:Staphylococcal Infections / Q000517:prevention & control; D013211:Staphylococcus aureus / Q000737:chemistry / Q000235:genetics / Q000276:immunology*; D014611:Vaccination
D001428:Bacterial Vaccines; D011135:Polysaccharides, Bacterial